tradingkey.logo
tradingkey.logo

Sun Pharma Announces Us FDA Acceptance Of Supplemental Biologics License (Sbla) Application For Ilumya® (Tildrakizumab-Asmn) For The Treatment Of Adults With Active Psoriatic Arthritis

ReutersMar 16, 2026 11:34 AM

- Sun Pharmaceutical Industries Ltd SUN.NS:

  • SUN PHARMA ANNOUNCES US FDA ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS LICENSE (SBLA) APPLICATION FOR ILUMYA® (TILDRAKIZUMAB-ASMN) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

  • SUN PHARMA - FDA REGULATORY ACTION DATE FOR ILUMYA SBLA EXPECTED BY OCTOBER 29, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI